Ascendiant Capital Markets Lowers AIM ImmunoTech (NYSE:AIM) Price Target to $5.00

AIM ImmunoTech (NYSE:AIM) had its target price lowered by Ascendiant Capital Markets from $5.25 to $5.00 in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

AIM ImmunoTech Price Performance

AIM stock opened at $0.33 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.17. The stock’s 50 day moving average price is $0.35 and its 200 day moving average price is $0.39. The firm has a market cap of $16.89 million, a P/E ratio of -0.51 and a beta of -0.39. AIM ImmunoTech has a 1 year low of $0.25 and a 1 year high of $0.68.

AIM ImmunoTech (NYSE:AIM) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. The business had revenue of $0.05 million during the quarter.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC bought a new stake in AIM ImmunoTech Inc. (NYSE:AIM) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned 7.92% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is currently owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).